CDKN2A and cancer: Molecular validation of IHC for RB in UC was performed prior to study enrollment and IHC for p16 is in widespread clinical use and correlates with CDKN2A loss reliably in other cancers.23 We accurately selected patients without loss of Rb (0 of 12 enrolled patients had Rb loss determined with NGS).